Austin Health

Title
Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial.
Publication Date
2022-12
Author(s)
McMahon, James H
Lau, Jillian S Y
Coldham, Anna
Roney, Janine
Hagenauer, Michelle
Price, Sally
Bryant, Mellissa
Garlick, Jill
Paterson, Anne
Lee, Sue J
O'Bryan, Jess
Hearps, Anna
Tachedjian, Gilda
Pinskier, Henry
Phillips, Cameron
Garrow, Stuart
Pinskier, Nathan
Melvin, Robert
Blakeway, Luke
Wisniewski, Jessica A
Byers, Sally
Badoordeen, Gnei Z
Pereira, Stephanie
Pragastis, Katherine
Trubiano, Jason
Chua, Kyra Y L
Kainer, Marion
Molton, James S
Gardiner, Bradley J
Pierce, Anna B
Cheng, Allen
Rogers, Benjamin A
Peleg, Anton Y
Subject
COVID-19
Favipiravir
Randomised clinical trial
Type of document
Journal Article
OrcId
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
DOI
10.1016/j.eclinm.2022.101703
Abstract
Well tolerated antivirals administered early in the course of COVID-19 infection when the viremia is highest could prevent progression to severe disease. Favipiravir inhibits SARS-CoV-2 viral replication in vitro with evidence of clinical benefit in open label trials. Placebo controlled studies of people with early symptomatic COVID-19 with regular assessments of SARS-CoV-2 viral load can determine if it has an antiviral effect and improves clinical outcomes.
Link
link
Citation
EClinicalMedicine 2022; 54
Jornal Title
EClinicalMedicine
ISSN
2589-5370

Files:

NameSizeformatDescriptionLink